Escitalopram and duloxetine in major depressive disorder: A pharmacoeconomic comparison using UK cost data

PharmacoEconomics

Volumn 26, Issue 11, 2008, Pages 969-981

  Wade, Alan G ^a   Fernández, José Luis ^b   François, Clément ^c   Hansen, Karina ^c   Danchenko, Natalya ^c   Despiegel, Nicolas ^c  

^a CPS Research   (United Kingdom)

^b LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^c Lundbeck   (France)

Author keywords

Cost effectiveness; Depression, treatment; Duloxetine, therapeutic use; Escitalopram, therapeutic use; Randomised controlled trials

Indexed keywords

DULOXETINE; ESCITALOPRAM; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ABSENTEEISM; ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL LEAVE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT RESPONSE; UNITED KINGDOM;

ABSENTEEISM; ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SICK LEAVE; THIOPHENES; YOUNG ADULT;

EID: 53849103635     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826110-00008     Document Type: Article

References (49)

1. Sonawalla SB, Fava M. Severe depression: is there a best approach? CNS Drugs 2001; 15 (10): 765-76
2. Thase ME. Treatment of severe depression. J Clin Psychiatry 2000; 61 Suppl. 1: 17-25
3. Murray CJ, Lopez AD. Evidence-based health policy: lessons from the Global Burden of Disease Study. Science 1996 Nov 1; 274 (5288): 740-3
4. Lepine JP, Gastpar M, Mendlewicz J, et al. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997 Jan; 12 (1): 19-29
5. Kessler RC, Akiskal HS, Ames M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of US workers. Am J Psychiatry 2006 Sep; 163 (9): 1561-8
6. Ferrier IN. Treatment of major depression: is improvement enough? J Clin Psychiatry 1999; 60 Suppl. 6: 10-4
7. Frampton JE, Plosker GL. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs 2007; 21 (7): 581-609
8. Sir A, D'Souza RF, Uguz S, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 2005 Oct; 66 (10): 1312-20
9. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001 Sep 1; 50 (5): 345-50
10. Azorin JM, Llorca PM, Despiegel N, et al. Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder [in French]. Encephale 2004 Mar-Apr; 30 (2): 158-66
11. Murdoch D, Keam SJ. Escitalopram: a review of its use in the management of major depressive disorder. Drugs 2005; 65 (16): 2379-404
12. Sanchez C. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol 2006 Aug; 99 (2): 91-5
13. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005 May; 20 (3): 131-7
14. Boulenger JP, Huusom AK, Florea I, et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006 Jul; 22 (7): 1331-41
15. Yevtushenko VY, Belous AI, Yevtushenko YG, et al. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin Ther 2007 Nov; 29 (11): 2319-32
16. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50 (1): 57-64
17. Khan A, Bose A, Alexopoulos GS, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig 2007; 27 (7): 481-92
18. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007 Jul; 23 (7): 1605-14
19. Montgomery SA, Andersen HF. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006 Sep; 21 (5): 297-309
20. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004 Sep; 65 (9): 1190-6
21. Llorca PM, Fernandez JL. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs venlafaxine extended-release formulation. Int J Clin Pract 2007 Apr; 61 (4): 702-10
22. Croom KF, Plosker GL. Escitalopram: a pharmacoeconomic review of its use in depression. Pharmacoeconomics 2003; 21 (16): 1185-209
23. Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005; 23 (2): 155-67
24. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed [text revision] (DSM-IVTR). Washington, DC: American Psychiatric Publishing, Inc., 1994
25. Sobocki P, Ekman M, Agren H, et al. Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health 2007 Mar-Apr; 10 (2): 153-60
26. Steel RGD, Torrie JH. Principles and procedures of statistics: a biometrical approach. 2nd ed. New York: McGraw-Hill Book Company, 1980
27. Personal Social Services Research Unit (PSSRU). Unit costs of health and social care. Canterbury (UK): University of Kent, 2006
28. UK Department of Health; National Health Service. Reference costs 2006 collection: guidance [online]. Available from URL: http://www.dh.gov.uk [Accessed 2007 Feb 23]
29. Wonderling D, Vickers AJ, Grieve R, et al. Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care. BMJ 2004 Mar 27; 328 (7442): 747
30. National Statistics. First release: 2006 annual survey of hours and earnings. 2006 Oct 26 [online]. Available from URL: http://www.statistics.gov. uk/pdfdir/ashe1006.pdf [Accessed 2008 Jan 30]
31. Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005 Sep-Oct; 8 (5): 521-33
32. Netten A, Rees T, Harrison G. Unit costs of health and social care 2001 [online]. Available from URL: http://www.pssru.ac.uk/pdf/UC2001/ UnitCosts2001ALL.pdf [Accessed 2008 Mar 5]
33. Wang PS, Simon G, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res 2003; 12 (1): 22-33
34. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001 Jul; 20 (4): 461-94
35. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998 Dec; 7 (8): 723-40
36. van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994 Sep-Oct; 3 (5): 309-19
37. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Hall & Chapman, 1993
38. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993 Nov; 54 (11): 405-18
39. Winkler D, Pjrek E, Moser U, et al. Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria. Hum Psychopharmacol 2007 Jun; 22 (4): 245-51
40. Wittchen HU, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002; 63 Suppl. 8: 24-34
41. Moller H-J, Langer S, Schmauß M. Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany. Pharmacopsychiatry 2007; 40: 53-7
42. Wimo A, Winblad B, Engedal K, et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 2003; 15 (1): 44-54
43. Sculpher MJ, Poole L, Cleland J, et al. Low doses vs high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group. Eur J Heart Fail 2000 Dec; 2 (4): 447-54
44. Caro JJ, Getsios D, Raggio G, et al. Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis. Headache 2001 May; 41 (5): 456-64
45. Drummond MF, Becker DL, Hux M, et al. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003 Aug; 124 (2): 526-35
46. Legendre CM, Norman DJ, Keating MR, et al. Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation. Transplantation 2000 Nov 27; 70 (10): 1463-8
47. Ekman M, Zethraeus N, Jonsson B. Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. Pharmacoeconomics 2001; 19 (9): 901-16
48. Manca A, Willan AR. 'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data. Pharmacoeconomics 2006; 24 (11): 1101-19
49. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000. J Clin Psychiatry 2003; 64 (12): 1465-75